Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Older adult patients (ie, those aged ≥60 years) undergoing surgery for hip fracture repair frequently experience loss of muscle mass and strength due to poor mobility and delayed functional recovery. No proven treatment is currently available to enhance recovery of physical function in this growing patient population. This study aimed to investigate whether bimagrumab, a human monoclonal antibody targeting activin type 2 receptors, can improve post-surgical recovery. METHODS: who had undergone internal fixation or hemiarthroplasty for a proximal femoral fracture (confirmed by radiography) in the previous 6 weeks were eligible. Patients with a history of a high-energy subtrochanteric fracture or any other lower limb fracture in the past 6 months, or any major surgery of the lower limbs in the past 3 months were excluded. Participants were randomly assigned (2:1:2:2) via interactive response technology to receive intravenous treatment with placebo, bimagrumab 70 mg, bimagrumab 210 mg, or bimagrumab 700 mg every 4 weeks for 24 weeks. Participants, investigators, site personnel, and study sponsor personnel in participating countries were masked to treatment assignment. The primary endpoint was the change from baseline in total lean body mass, measured by dual-energy x-ray absorptiometry, at week 24 in the full analysis set, which included all randomised participants who had received at least one dose of the assigned treatment. Key secondary endpoints included changes in habitual gait speed (measured in m/s) and short physical performance battery score between baseline and 24 weeks. Safety and tolerability were assessed by recording adverse events and vital signs on weeks 4, 8, 12, 24, and 48, and by laboratory assessments and electrocardiography at the screening visit and on days 1, 84, and 168. Safety was assessed in all randomised participants who had received at least one dose of study drug, analysed according to treatment received. This study was registered with ClinicalTrials.gov, NCT02152761. FINDINGS: Between Sept 16, 2014, and Dec 15, 2017, 384 patients were screened, of whom 250 patients were enrolled and randomly assigned to the placebo group (n=72), the bimagrumab 70 mg group (n=34), the bimagrumab 210 mg group (n=69), or the bimagrumab 700 mg group (n=75). A total of 207 (83%) participants completed the 24-week treatment period. There was a significant absolute increase in lean body mass from baseline compared with placebo (0·2 kg [SD 2·0]) in the bimagrumab 210 mg group (1·9 kg [1·7]; p<0·0001) and in the bimagrumab 700 mg group 2·8 kg [2·2]; p<0·0001) but not in the bimagrumab 70 mg group (0·6 kg [SD 2·2]; significance not assessed). Changes in habitual gait speed and short physical performance battery scores between baseline and week 24 were not significantly different across the treatment groups, suggesting no enhancement of physical recovery with bimagrumab over placebo. Bimagrumab was safe and well tolerated. The most frequently reported treatment-emergent adverse events were falls (six [18%] of 34 participants in the bimagrumab 70 mg group; 12 [17%] of 69 participants in the bimagrumab 210 mg group; 14 [19%] of 75 participants in the bimagrumab 700 mg group; and 13 [18%] of 72 participants in the placebo group), muscle spasms (two [6%] in the bimagrumab 70 mg group; 17 [25%] in the bimagrumab 210 mg group; 12 [16%] in the bimagrumab 700 mg group; and six [8%] in the placebo group), and arthralgia (five [15%] in the bimagrumab 70 mg group; six [9%] in the bimagrumab 210 mg group; nine [12%] in the bimagrumab 700 mg group; and five [7%] in the placebo group). Six deaths were reported during the study, none of which were considered by investigators as related to the study drug. INTERPRETATION: Bimagrumab treatment for 24 weeks led to dose-dependent, significant increases in lean body mass in older patients recovering from hip fracture surgery when compared with placebo. However, no functional benefit was observed in recovery of mobility or lower extremity function following bimagrumab treatment compared with placebo. FUNDING: Novartis Pharma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deutz, N. E. P., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznariç, Z., Nair, K. S., et al. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.04.007 · Cited by 1,738
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
Short physical performance battery and all-cause mortality: systematic review and meta-analysis
Pavasini, R., Guralnik, J., Brown, J. C., di Bari, M., Cesari, M., Landi, F., Vaes, B., Legrand, D., Verghese, J., Wang, C., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0763-7 · Cited by 911
Substantial skeletal muscle loss occurs during only 5 days of disuse
Wall, B. T., Dirks, M. L., Snijders, T., Senden, J. M. G., Dolmans, J., & van Loon, L. J. C. (2014) · Acta Physiologica · doi:10.1111/apha.12190 · Cited by 346
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
Papanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J. (2013) · The Journal of nutrition, health and aging · doi:10.1007/s12603-013-0335-x · Cited by 196
Self-citationRooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Self-citationMorvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Polkey, M. I., Praestgaard, J., Berwick, A., Franssen, F. M. E., Singh, D., Steiner, M. C., Casaburi, R., Tillmann, H.-C., Lach-Trifilieff, E., Roubenoff, R., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0286oc · Cited by 111
Self-citation
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Sarcopenia, osteoporosis and frailty
Gielen, E., Dupont, J., Dejaeger, M., & Laurent, M. R. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155638 · Cited by 258
Current and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Effect of Bimagrumab on Body Composition: A Systematic Review and Meta-Analysis
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02825-4 · Cited by 45
“[8, 10, 12, 18, 19] Although not included in the meta-analysis because of unit incompatibility of the results, Rooks, Laurent et al. [8] also identified an increase in fat-free body mass and 3).”
InfluentialChen, Y. C., Chen, W.-C., Liu, C.-W., Huang, W.-Y., Lu, I., Lin, C. W., Huang, R. Y., Chen, J. S., & Huang, C. H. (2023) · European Review of Aging and Physical Activity · doi:10.1186/s11556-023-00333-4 · Cited by 34
“Novel agents such as bimagrumab (human monoclonal antibody targeting activin type 2 receptors) [100] and MK0733 (selective androgen receptor modulator) [36] have the potential to improve skeletal muscle mass, but our results show no benefit on muscle function and physical performance.”
Background
Metadata
- Authors
- Hofbauer, L. C., Witvrouw, R., Varga, Z., Shiota, N., Cremer, M., Tanko, L. B., Rooks, D., Auberson, L. Z., Arkuszewski, M., Fretault, N., Schubert-Tennigkeit, A. A., Papanicolaou, D. A., & Recknor, C.
- Venue
- The Lancet Healthy Longevity
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 2
- Issue
- 5
- Pages
- e263-e274
- ISSN
- 2666-7568 (ISSN-L)
- OpenAlex
- W3159353892
- Cited by
- 38
- References
- 9
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. https://app.cochat.ai/papers/10.1016/s2666-7568(21)00084-2
- The paper
- Hofbauer, L. C., Witvrouw, R., Varga, Z., Shiota, N., Cremer, M., Tanko, L. B., Rooks, D., Auberson, L. Z., Arkuszewski, M., Fretault, N., Schubert-Tennigkeit, A. A., Papanicolaou, D. A., & Recknor, C. (2021). Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. The Lancet Healthy Longevity. https://doi.org/10.1016/s2666-7568(21)00084-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.